GSK’s Genelabs Acquisition To Focus On Hepatitis C Compounds
Despite the tough capital environment, Genelabs gets $1.30 per share, restoring much of the value its stock lost during 2008.
Despite the tough capital environment, Genelabs gets $1.30 per share, restoring much of the value its stock lost during 2008.